Research endeavors to identify the cellular repair gene modulation activated by applying C.A.R. E. RadioImmunotherapySM low-dose radiation to patients prior to cancer treatment.
Henderson, NV, March 15, 2017 – Radiation Barrier, an adaptive Immunotherapy company that addresses the unmet needs of cancer treatment toxicity, is conducting the first known in-vivo human trials to validate the benefits of low-dose radiation to reduce the unwanted toxic side effects of cancer treatment. Pre-clinical research confirms that low-dose radiation activates genetic pathways involved in multiple layers of cellular protection.
Radiation Barrier’s technology modulates genes and proteins at the cellular level as part of a natural adaptive response that protects healthy cells from damage and stops disease progression. The ability to trigger an adaptive genetic response is important to the development of novel drug therapies and immune system diagnostic tests and has tremendous potential to accelerate and lower the cost of personalized drug development. Through its patented C.A.R.E. RadioImmunotherapySM protocol, Radiation Barrier addresses the costly and devastating damage caused by diseases and their treatments so that patients can enjoy improved treatment efficacy and quality of life during and after treatment.
The C.A.R.E. RadioImmunotherapySM innovation stems from the scientific discovery generated from the U.S. Department of Energy’s low-dose radiation program, a $250 million body of research conducted over 16 years with 24 universities and three national labs that resulted in more than 700 peer-reviewed papers. Dr. Richard Blankenbecler, a world-renowned professor of Theoretical Physics at Stanford University’s SLAC National Laboratory, was one of the first to recognize the medical applications of the DOE research. In 2008, he developed and patented the process to activate a protective DNA response using low-dose radiation that modulates genes and proteins to initiate cellular repair for cancer treatment toxicity.
“Until now, the medical community has not applied the insights from the DOE research that low-dose radiation activates a positive adaptive response in humans, specifically to the treatment of cancer and other diseases”, noted Dr. Blankenbecler. “Radiation Barrier was created to extend and apply these insights to the clinical application of the beneficial effects of low-dose radiation and to discover other potential catalysts to adaptive response in humans,” adds Blankenbecler.
Fully tabulated genomic, proteomic, and toxicity results are expected by Summer 2017 and will directly measure reduction in inflammation, toxicity, and identify the genetic pathways involved in the adaptive response to radiation.
Radiation Barrier is an immunotherapy company that modulates genes and proteins at the cellular level as part of a natural adaptive response activated by its patented C.A.R.E. RadioImmunotherapySM low-dose radiation protocol that protects healthy cells from damage and stops disease progression.
With direct applications to cancer treatment and neurological, autoimmune, and inflammatory diseases, Radiation Barrier’s C.A.R.E RadioImmunotherapy addresses the costly and devastating damage caused by diseases and their treatments, so that patients can enjoy improved treatment efficacy and quality of life during and after treatment.
Radiation Barrier’s ability to trigger an adaptive genetic response is `important to the development of novel drug therapies, immunotherapy and cellular immune system diagnostic tests and has tremendous potential to accelerate and lower the cost of personalized drug development.
For more information about Radiation Barrier, visit www.radbarrier.com
Media Inquiries: Carol Levey, Public Relations email@example.com (818) 692-6549
Investor Relations: Linda Ritchie, CEO firstname.lastname@example.org (949) 640-9170